Dihydropyridine calcium channel blockers (DHPCCBs) are widely used to treat hypertension
and chronic coronary artery disease. One common adverse effect of DHPCCBs is peripheral …

Summary Abstract Olmesartan medoxomil (Olmetec®, Benicar®) is an angiotensin II type 1
(AT 1) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of …

Studies have shown that angiotensin converting enzyme inhibitors (ACEIs) are superior in
primary and secondary prevention for cardiac mortality and morbidity to angiotensin receptor …

Background The prevalence of hypertension and its associated complications are markedly
growing. Most patients need more than one drug to achieve blood pressure (BP) target …

This work aims to improve the dissolution of the poorly water soluble drug olmesartan
medoxomil by using the surface solid dispersion (SSD) technique. Insoluble carriers, namely …

Introduction Patients with stage 2 hypertension require large absolute reductions in blood
pressure (BP) to achieve recommended BP goals. Combination therapy with the direct renin …

A novel 96-microwell-based spectrophotometric assay has been developed and validated
for determination of olmesartan medoxomil (OLM) in tablets. The formation of a colored …

The objective of the present study was to systematically review the clinical and economic
outcomes of olmesartan as monotherapy or in combination with other antihypertensive …

Calcium channel blockers (CCBs) play a vital role in the management of hypertension.
Peripheral edema is the most common side effect reported with CCB monotherapy …

Background This study was to evaluate the efficacy and safety of triple fixed-dose
combination (FDC) therapy with olmesartan medoxomil (OM) 20 mg, amlodipine (AML) 5 …